Table 1.
Six articles related to omalizumab for HIES.
| References | Sex/age (y) (mutated gene) | Main symptoms | Medical history | Dose and period omazulimab | Serum IgE-level (IU/mL) (before/after) | Change in symptoms |
|---|---|---|---|---|---|---|
| Bard et al. (10) | F/26 (-) | Eczematous dermatitis, asthma | Infectious bronchitis, pneumonias, cystitis | 450 mg every 2 weeks, 3 m | 1,083/– | Symptoms improved after 1 mo, complete remission after 3 mo |
| Marcotte (11) | M/14 (-) | Severe atopic dermatitis asthma, atopic keratoconjunctivitis | Frequent respiratory infections, skin abscesses, allergic rhinitis, | 375 mg every 2 weeks, 3 m | 9,408/– | No active eczematous, pruritus and photophobia, improved in both eyes, vision improved, ACT score and FEV1 increase |
| Chularojanamontri et al. (12) | F/32 (-) | Pruritic skin lesions | Scalp abscesses, alopecia | 300 mg every 2 weeks, 1 m | 17,300/– | Eczematous lesions improved |
| Akbaş et al. (13) | F/12 (-) | Flexural eczema, intense pruritus | Frequent upper respiratory tract infections, mentalmotor retardation | 300 mg every 1 month, 5 m (no benefit) changed to 300 mg every 2 weeks, 1 m | 3,800/1,376 | Relief of the pruritus and skin lesions |
| Alonso-Bello et al. (9) | M/37 (-) | Atopic dermatitis, generalized itching, peeling | – | 300 mg every 2 weeks, 6 w (effective) 350 mg every 2 weeks,4 y | 12,700/439 | After 6 weeks, eczematous lesions improved; after 4 years, skin lesions exacerbation |
| Gomes et al. (14) | M/33 (STAT3 mutation) | Recalcitranteczema, | Folliculitis, onychomycosis, respiratory infections, esophageal candidiasis | 375 mg every 2 weeks, 12 m | 11,802/8,660 | skin lesions and pruritus improved |